The Magazine for Sleep Professionals
Monday, September 28, 2026
By Nathan Costiuc, MSN, APRN, FNP-BC Inspiratory muscle training, also known as IMT, is an emerging area of research in the treatment of Obstructive Sleep Apnea (OSA). And although that research is in its early stages, IMT has shown promise as an effective way to improve OSA as an adjuvant […]
Testing in accordance with ISO 18562 and ISO 10993 standards conducted by five certified, independent testing laboratories in the US and Europe This update is intended to provide healthcare providers, patients, and other stakeholders with updated information on the testing results to date. Philips will continue to provide regular updates as new […]
Incannex Healthcare Limited (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has completed analysis of data from the Phase 2 proof-of-concept clinical trial investigating IHL-42X for treatment of obstructive sleep […]
Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the use of Nyxoah’s next-generation Genio® 2.1 system for use in the Company’s DREAM U.S. IDE pivotal study. Genio® 2.1’s upgrades are entirely related to the external components of the Genio® system, as the implantable stimulator remains […]
ProSomnus, a leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the results of three studies evaluating its FDA-cleared Oral Appliance Therapy (OAT) devices in the treatment of OSA. ProSomnus will share data in three poster presentations at SLEEP 2022, the Annual Meeting of […]
SleepRes, LLC introduces the V̇-Com™ at SLEEP2022/APSS this week, a revolutionary device to make CPAP more comfortable and increase adherence. The V̇-Com™, which softens peak inspiratory flow, makes starting CPAP easier and faster. “This may be the most important comfort factor in the PAP circuit since we developed BiPAP over […]
In June 2021, Philips Respironics, initiated a voluntary recall notification in the US/field safety notice in other countries for certain sleep and respiratory care products to address potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in certain CPAP, BiPAP and mechanical ventilator devices. At the time the […]
With a grant from the National Institute of Science, Eclipse™ will launch late in the third quarter of 2022. Eclipse uses MagSeal™ technology to ensure a rapid on/rapid off interface. Like the DreamPort also by Bleep, Eclipse™ optimizes PAP users comfort by removing all of the headgear and straps and […]
ProSomnus has announced the results of three studies evaluating its oral appliance therapy devices in the treatment of obstructive sleep apnea. ProSomnus presented the data in three poster presentations at the 2022 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting, held from May 13-15 in Dallas, Texas. Emerging data […]
The FDA’s Center for Devices and Radiological Health is proposing that an order should be issued, under section 518(b) of the Federal Food, Drug, and Cosmetic Act, to require Philips Respironics (“Philips”) to submit a plan for the repair, replacement, or refund of the purchase price of the recalled devices […]
